Watch out Moderna: John Maraganore, ARCH and Beam are hatching a platform play 'to lead the future of RNA therapies'
Giuseppe Ciaramella joined Moderna in 2014, back when the mRNA specialist only employed about 70 people. There, as CSO of the infectious disease division, he helped build the initial mRNA vaccine pipeline and steered Moderna’s first vaccine program toward an IND.
He left for Beam Therapeutics four years later, before a wildly successful Covid-19 vaccine propelled Moderna to the biotech hall of fame.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.